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Peripheral natural killer (NK) cells upregulate T-bet and downregulate Eomes, the key 
transcription factors regulating NK cell maturation and function during the last maturation 
steps toward terminally differentiated effector cells. During this process, NK cells acquire 
killer immunoglobulin-like receptors (KIR) and effector functions, such as cytotoxicity 
and target cell-induced cytokine production. Inhibitory KIR are pivotal in the control of 
effector functions, but whether they also modulate T-bet/Eomes expression is unknown. 
We have measured T-bet/Eomes levels, KIR expression, and effector functions of 
maturing CD94negCD56dimNK cells using CD57 as surface marker for maturation. Our 
cohort consisted of 23 healthy blood donors (HBD) homozygous for the KIR A haplotype 
that contains only inhibitory KIR2DL1 (ligand HLA-C2), KIR2DL3 (ligand HLA-C1), and 
KIR3DL1 (ligand HLA-Bw4). We confirm that during maturation of NK cells, the number 
of KIR increases, levels of T-bet/Eomes are modulated, and that cells acquire effector 
functions, such as cytotoxicity (CD107) and target cell-induced cytokine production 
(TNF-α). Because maturation was associated with the increase of the number of KIR 
as well as with the modulation of T-bet/Eomes, the number of KIR correlated with the 
extent of T-bet/Eomes modulation. However, whether the KIR were triggered by their 
cognate HLA ligands or not had no impact on T-bet and Eomes expression, indicating 
that modulation of T-box transcription factors during NK cell maturation does not depend 
on signals conveyed by KIR. We discuss the relevance of this finding in the context of 
models of NK cell maturation while cautioning that results obtained in a perhaps quite 
heterogeneous cohort of HBD are not necessarily conclusive.
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inTrODUcTiOn
Natural killer (NK) cells are involved in the early response to pathogens as well as in the 
recognition of autologous cells under stress induced by infection or transformation (1). 
Maturation toward an end-stage cytotoxic effector cell is associated with the loss of CD94 
and acquisition of killer immunoglobulin-like receptors (KIR), of markers such as CD57 and 
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of fine-tuning of effector functions (2–5). Activation of NK 
cells depends on an aggregate of signals conveyed by various 
activating and/or inhibitory receptors. Responsiveness to self 
is reduced through the triggering of inhibitory KIR by their 
ligands that consist of allelic variants of MHC molecules that 
are clustered in three groups, HLA class I ligands (HLA-C1, 
HLA-C2, and HLA-Bw4). NK cells without inhibitory KIR 
for self may remain harmless either because acquisition of 
the most potent effector functions (arming) requires interac-
tion of inhibitory KIR with self-ligands or because NK cells 
stimulated by activating receptors in the absence of interaction 
of inhibitory KIR with self reduce responsiveness. These latter 
two processes are referred to as “licensing” (6, 7) and “educa-
tion” (8, 9). The ensuing level of responsiveness may still be 
adapted to their immunological environment in mature NK 
cells, but the molecular mechanisms have not been established 
yet [recently reviewed in Ref. (10)].
T-bet and Eomesodermin (Eomes), two T-box transcription 
factors, are master regulators of T cell effector functions, includ-
ing cytotoxicity and interferon-gamma (IFN-γ) production 
(11,  12). Furthermore, recent reports have shown that these 
two transcription factors also regulate maturation and function 
of NK cells. Murine (13) and human (14, 15) NK cells express 
T-bet and Eomes constitutively, and mice lacking both T-bet 
and Eomes are completely deprived of NK cells (16). Moreover, 
the two T-box transcription factors are modulated during NK 
cell differentiation (14, 17, 18) and are necessary for mainte-
nance and differentiation of peripheral NK cells, while their 
deletion in mature NK cells results in reversion to an immature 
phenotype (16).
Mature NK cells express more licensing/educating KIR, are 
more cytotoxic, and proliferate less (2, 4). Whether they produce 
more cytokines after stimulation with target cells remains under 
debate (4, 19). Furthermore, they have downregulated Eomes and 
upregulated T-bet (14, 20). The concurrence of these processes 
has made it difficult to determine whether licensing is associated 
with, or the cause of the modulation of effector functions as well 
as T-bet/Eomes expression. It has been difficult to establish that 
signals conveyed by inhibitory KIR encountering their ligands 
induce maturation. Indeed, one could also argue that the increase 
in effector functions found to be correlated with the expression 
of such KIR simply reflects a licensing-independent concomitant 
NK cell maturation (4).
T-bet and Eomes induce NK cell maturation by suppressing 
CD27 and c-kit and upregulating S1P5 and KLRG1 [recently 
reviewed in Ref. (21)]. Hence, if signals through licensing 
receptors induce maturation, one would expect that the same 
signals would modulate the levels of T-bet and Eomes first. In 
this report, we measured T-bet and Eomes levels in maturing NK 
cells in 23 healthy blood donors (HBD) that were homozygous 
for the KIR A haplotype, which comprises only inhibitory KIR 
for their respective HLA-C or HLA-Bw4 ligands. We found that 
T-bet and Eomes were modulated in parallel with the increase 
of KIR, but whether the ligand for the KIR was present or not 
had no impact. This finding strengthens the model of a recently 
put forward (4), licensing-independent concomitant NK cell 
maturation.
MaTerials anD MeThODs
Dna extraction and Kir genotyping
Killer immunoglobulin-like receptors genotyping was performed 
on DNA extracted from 400  μl of blood using QIAmp Blood 
Mini kit (Qiagen) with the KIR Genotyping SSP kit (Invitrogen) 




HLA-A, B, C typing was performed by PCR-SSO hybridization 
on microbeads arrays (Luminex technology), using the LabType 
high definition reagents (One Lambda, Canoga Park, CA, USA). 
When required for the assignment of the HLA-C1 and -C2 groups, 
typing ambiguities were resolved by PCR-SSP using Olerup SSP 
kits (Milan Analytika AG, La Roche, Switzerland).
Facs analysis, effector Function Tests
Peripheral blood mononuclear cells (PBMCs) from AA hap-
lotype homozygous donors blood from the Geneva University 
Hospitals blood transfusion center who gave informed consent 
by signing a standard form approved by the hospital’s ethical 
commission were isolated from anticoagulated blood by Ficoll 
density gradient centrifugation. We performed FACS analysis with 
monoclonal antibodies specific for the following antigens: CD158a 
(FITC, HP-MA4, Biolegend), CD57 (PECF594, clone NK1, BD 
Biosciences), CD94 (PerCPCy5.5, clone HP-3D9, BD Biosciences), 
CD158b (PEVio770, clone DX27, Miltenyi), CD158e (Alexa700, 
clone DX9, Biolegend), CD3 (APCH7, clone SK7, BD Biosciences), 
CD56 (BV421, cloneHCD56, Biolegend), CD107a (BV605, clone 
H4A3, Biolegend), TNF-α (BV605, clone MAb11, Biolegend), 
IFN-γ (BV605, clone 4S.B3, Biolegend), Eomes (eFluor 660, clone 
WD1928, e-Bioscience), and T-bet (PE, clone 4B10, e-Bioscience).
Effector functions were measured by stimulating PBMC at 37°C 
with K562 (cytotoxicity, TNF-α production) or with IL2/12/18 
(IFN-γ production) as described before (20). Anti-CD107a was 
added at the start of the culture set up to measure degranulation. 
After 1 h, GolgiStop and GolgiPlug (BD Biosciences) were added, 
and cells were cultured for a further 3 h (CD107 and TNF-α) or 
5 h (IFN-γ detection).
Intracellular staining for TNF-α, IFN-γ, Eomes, and T-bet 
was performed overnight at 4°C on permeabilized cells with 
FoxP3/transcription factor staining buffer set (e-Bioscience). 
CD3negCD56neg lymphocytes in the same blood sample were 
considered as Eomes and T-bet negative cells.
Data acquired on a Gallios 3 cell analyzer (BD Biosciences) 
were analyzed with FlowJo software (Tree Star Inc.) with the gates 
depicted in Figure 1. The first two gates (Figures 1A,B) were used 
to demarcate NK cells as CD3negCD56pos cells with the FSC/SSC of 
lymphocytes. CD56bright and CD56dim NK cells were discriminated 
on basis of the level of CD56-expression (Figure 1C). Maturation 
state (CD57), effector functions, and T-bet/Eomes levels of 
CD94neg (Figure  1D), CD56dim NK cells were measured in the 
respective eight subsets defined by the expression KIR2DL1, 
KIR2DL3, and KIR3DL1 (Figures  1E,F). Levels of T-bet and 
Eomes are expressed as mean fluorescence intensity ratio (MFIR), 
FigUre 1 | gating strategies for Kir subset analysis. (a) Lymphocyte gates on FSC and SSC. (B) NK cell defined as CD56posCD3neg lymphocytes. (c) 
CD56bright and CD56dim NK cells according to the level of CD56-expression and gate on CD56dimCD94neg NK cells used for further analysis. (D–F) CD56dimCD94neg 
cells according to KIR expression (eight subsets). Q1: KIR2DL1negKIR2DL3negKIR3DL1pos, Q2: KIR2DL1posKIR2DL3negKIR3DL1pos, Q3: 
KIR2DL1negKIR2DL3negKIR3DL1neg, Q4: KIR2DL1posKIR2DL3negKIR3DL1neg, Q5: KIR2DL1negKIR2DL3posKIR3DL1pos, Q6: KIR2DL1posKIR2DL3posKIR3DL1pos, Q7: 
KIR2DL1negKIR2DL3posKIR3DL1neg, Q8: KIR2DL1posKIR2DL3posKIR3DL1neg. Examples of fluorescence intensity of CD57 (g), Eomes (h) and T-bet (i) according to the 
number of KIR expressed with their respective negative controls.
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representing the mean fluorescence of T-bet/Eomes divided by 
the fluorescence of T-bet/Eomes negative CD3negCD56neg cells in 
the same sample. The percentage of CD107pos cells is expressed 
as %CD107pos NK cell after stimulation with K562 – % CD107pos 
unstimulated NK cell.
statistical analysis
Non-parametric Wilcoxon matched-pairs signed rank test or 
Mann–Whitney test were used to compare groups, p values >0.05 
were considered as not statistically significant.
resUlTs
We have studied maturing NK cells in 23 KIR A haplotype 
homozygous HBD that comprise only the inhibitory variant of 
KIR2DL1, KIR2DL3, and KIR3DL1. This allowed us to measure 
the effect of the presence or absence of HLA ligands on inhibi-
tory KIR using monoclonal antibodies that also recognize their 
activatory variants. Table  1 shows the KIR and HLA class I 
molecules expressed by the 23 HBD tested. As expected for KIR 
A haplotype homozygous individuals, NK cell subpopulations 
expressing KIR2DL1 and KIR2DL3 were present in all HBD. 
Two of 23 HBD lacked NK cells expressing KIR3DL1, which 
is owed to the fact that some KIR3DL1 allelic variants are not 
expressed at the protein level (22). The last three columns of 
the table show in which HBD the respective KIR encounter 
their cognate ligands [KIR2DL1↔C2, KIR2DL3↔C1, and 
KIR3DL1↔Bw4 epitope on HLA-B antigens as well as the 
HLA-A antigens (23, 24) marked in bold]. Hence, KIR2DL1 
encountered its cognate HLA ligand in 10/23 and KIR2DL3 
TaBle 1 | hla class i and Kir expression in the 23 hBD.
hBD hla-a hla-a hla-B hla-B epitopes B hla-c hla-c epitopes c Kir3Dl1 Kir2Dl3 Kir2Dl1
1 02:01 32:01c 15:01 40:02 Bw6/Bw6 02:02 03:03 C1/C2 a a a
2 02:01 30:02 15:01 35:01 Bw6/Bw6 01:02 04:01 C1/C2 a a
3 24:02 30:01 13:02 44:03 Bw4/Bw4 06:02 16:01 C1/C2 a a a
4 02:01 02:01 18:01 51:01 Bw4/Bw6 07:01 14:02 C1/C2 a a
5 02:01 11:01 18:03 39:09 Bw6/Bw6 07:01 07:02 C1/C2 a
6 02:01 25:01 13:02 35:01 Bw4/Bw6 07:01 07:02 C1/C2 a a
7 01:02 02:01 07:02 49:01 Bw4/Bw6 07:01 07:02 C1/C2 a a
8 02:01 23:01 49:01 51:01 Bw4/Bw4 02:02 07:01 C1/C2 a a a
9 01:01 01:01 57:01 57:01 Bw4/Bw4 06:02 07:01 C1/C2 a a a
10 01:01 11:01 49:01 52:01 Bw4/Bw4 07:01 12:02 C1/C2 a a
11 02:01 32:01 35:01 44:02 Bw4/Bw6 04:01 05:01 C2/C2 a a
12 01:01 11:01 15:01 35:01 Bw6/Bw6 03:03 04:01 C1/C2 a a
13 02:01 03:01 56:01 56:01 Bw6/Bw6 01:02 01:02 C1/C2 a
14 02:01 24:02 15:01 44:02 Bw4/Bw6 03:03 05:01 C1/C2 a a a
15 03:01 29:02 07:02 44:03 Bw4/Bw6 07:02 16:01 C1/C2 a a
16 02:01 26:01 13:02 58:01 Bw4/Bw4 06:02 07:01 C1/C2 b a a
17 24:02 30:02 38:01 40:01 Bw4/Bw6 03:04 12:03 C1/C2 b a
18 01:01 11:01 08:01 51:01 Bw4/Bw6 07:01 15:02 C1/C2 a a a
19 26:01 32:01 38:01 44:03 Bw4/Bw4 12:03 16:01 C1/C2 a a
20 02:01 24:02 35:01 44:02 Bw4/Bw6 01:02 01:02 C1/C2 a a
21 26:01 33:01 14:02 44:02 Bw4/Bw6 08:02 12:03 C1/C2 a a
22 01:01 68:01 08:01 39:01 Bw6/Bw6 07:01 12:03 C1/C2 a
23 23:01 31:01 07:02 08:01 Bw6/Bw6 07:01 07:02 C1/C2 a
aLicensed.
bKIR3DL1 not expressed (22).
cHLA-A*3201 with Bw4 epitope (23, 24).
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in 22/23 HBD, while KIR3DL1 was able to license NK cells 
in 15/23 HBD.
expression of eomes/T-bet/cD57 in 
relation to the number of Kir
Several reports have shown that NK cells upregulate CD57 
and increase the number of KIR expressed during matura-
tion. In parallel, CD56dim NK cells downregulate Eomes 
and upregulate T-bet. Using the gating strategy shown in 
Figure 1, we measured the levels of CD57, Eomes, and T-bet 
in CD56bright NK cells and in the eight NK cell subpopulations 
of CD56dimCD94neg NK cells expressing different combinations 
of KIR2DL1, KIR2DL3, and KIR3DL1. Figure  2 shows the 
results of our panel of 23 HBD and confirms (Figures 2A,B) 
that indeed CD57 levels on CD94negKIRposCD56dim NK cells are 
significantly higher than on CD94negKIRnegCD56dim NK cells, 
and that CD57 levels increase further with the number of KIR 
expressed (for comparison, CD57, Eomes and T-bet levels on 
CD56bright NK cells are shown). This was true when all KIR 
(Figure  2A) or only licensing KIR (Figure  2B) were consid-
ered. Furthermore, levels of Eomes that are significantly lower 
in CD56dim NK cells than in CD56bright NK cells (Figures 2C,D) 
are further downregulated with the acquisition of KIR. As 
expected, T-bet levels were the opposite of Eomes levels. 
CD56dim NK cells expressed more T-bet than their CD56bright 
counterparts, and these levels increased with the number of 
KIR expressed (Figures  2E,F). Again, whether all KIR were 
licensing (Figures 2D,F) or not (Figures 2C,E) did not seem 
to have a considerable impact.
eomes/T-bet/cD57 expression and 
effector Function of licensed and 
Unlicensed nK cells
To investigate the effect of licensing on Eomes/T-bet levels more 
precisely, we gated on CD56dim NK cells expressing a single KIR 
and tested the impact of the presence or absence of its HLA 
ligand. Furthermore, we gated on CD94neg NK cells to disregard 
the weaker inhibitory signals through CD94/NKG2A (25), of 
which the contribution to licensing is unclear. Figures  3A,B 
show that the expression of Eomes/T-bet in licensed NK cells 
was identical to the level in unlicensed NK cells. This was 
true for single KIR2DL1pos NK cells in the presence (HBD 
1–3, 8, 9, 11, 12, 14, 16, 18) or in the absence (HBD 4–6, 7, 
10, 13, 15, 17, 19–23) of its ligand HLA-C2 (Figure  3C) as 
well as for single KIR3DL1pos NK cells in the presence (HBD 
1, 3, 4, 6–11, 14, 15, 18–21) or in the absence (HBD 2, 5, 12, 
13, 16, 17, 22, 23) of its ligand HLA-Bw4 (Figure  3D). We 
were not able to compare the effect of the ligand HLA-C1 
on single KIR2DL3pos NK cells because our panel comprised 
only one HLA-C1 negative HBD (HBD 11), but the fact that 
the Eomes/T-bet levels in licensed single KIR2DL3pos NK cells 
(HBD 1–10, 12–23) was identical to the levels in (un)licensed 
single KIR2DL1pos or KIR3DL1pos NK cells did suggest that 
the effect of licensing in single KIR2DL3pos NK cells may also 
be negligible.
Licensed and unlicensed NK cells expressed similar lev-
els of CD57 (Figure  3E), but effector functions that were 
higher in cells expressing more KIR (data not shown) were 
to some extent affected by licensing. Licensed NK cells 
FigUre 2 | cD57 and T-bet are upregulated, while eomes is downregulated during nK cell maturation and Kir acquisition. Expression levels of CD57 
(a,B), eomes (c,D), and T-bet (e,F) in CD56bright or in CD56dim CD94neg cells according to the number of KIR (a,c,e) or licensing KIR (B,D,F) expressed. Medians 
are shown, and Wilcoxon matched-pairs signed rank test was used for statistical analysis, p values are indicated. As mentioned in the text, CD94pos NK cells have 
been excluded from analysis because, although the results are very similar (not shown), the inclusion of CD94pos NK cells would render the interpretation of the 
results more difficult.
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produced significantly more TNF-α than unlicensed NK cells 
(Figure  4A), and the most cytotoxic NK cells (Figure  4B) 
were licensed. Hence, we found that the effect of licensing on 
maturation and effector functions of human NK cells may be 
of secondary importance only, which in our opinion accords 
well with the variegated results on the effect of licensing on 
different effector functions of human NK cells reported by 
others (2, 4, 19).
FigUre 4 | impact of licensing on TnF-α production and cytoxicity in 
cD56dimcD94neg cells. TNF-αpos (a) and CD107pos (B) cells in 
CD56dimCD94neg cells expressing a single licensed (L) or unlicensed (U) KIR 
after culture for 3 h in presence of K562 target cells. Medians are shown, and 
Mann–Whitney test was used for statistical analysis, p values are indicated 
when significant.
FigUre 3 | licensing has no effect on eomes, T-bet, and cD57 expression. Eomes (a), T-bet (B), and CD57 (e) MFIR are shown in CD56dimCD94neg cells 
expressing a single licensed (L) or unlicensed (U) KIR. Eomes (c) and T-bet (D) MFIR are represented for each KIR separately. Medians are shown, and Mann–
Whitney test was used for statistical analysis.
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DiscUssiOn
The expression of the master regulators of NK cell differentiation 
T-bet and Eomes is modulated during the maturation toward 
end-stage cytotoxic NK cells. Cytokine-producing CD56bright NK 
cells express higher levels of Eomes and lower levels of T-bet than 
cytotoxic CD56dim NK cells, and the T-bet/Eomes ratio increases 
further during the last maturation steps toward terminally 
differentiated CD56dimCD57pos NK cells (14, 15, 20). During 
maturation, the number of KIR increases, markers such as CD94 
and CD62L are downregulated, CD57 is upregulated, and effector 
functions change (2–5).
There are indications that licensing favors maturation, but the 
extent thereof remains under debate (2, 4, 19). It is conceivable 
that licensing modulates T-bet and Eomes and that the ensuing 
upregulation of T-bet is at the origin of the increased cytotoxicity 
that is characteristic of mature NK cells. However, it may also be 
that licensing, upregulation of T-bet, and the increase of cytotox-
icity are maturation-associated, parallel processes.
To answer this question, we measured T-bet and Eomes levels 
in maturing NK cells that were licensed or not. We found no 
differences in T-bet/Eomes levels in licensed or unlicensed NK 
cells. Although this would indicate that licensing and modula-
tion of T-bet and Eomes are independent processes, we remain 
somewhat reluctant to draw such a firm conclusion based on 
the analysis of a panel of perhaps quite heterogeneous HBD. In 
humans, it might not be that easy to discriminate between cells 
that have matured in response to signals through licensing KIR 
or in response to cytokines (6, 7, 26, 27) produced during an 
inflammatory immune response. Indeed, mouse models have 
been somewhat more consistent regarding the effect of licensing 
on effector functions (6, 28, 29) than human studies (2, 4, 8, 19, 
30). Likewise, our results regarding the acquisition of effector 
functions or of a more mature phenotype of CD56dimCD94neg 
single KIRpos NK cells in the presence or absence of their cognate 
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HLA ligand were not very conclusive. Licensed NK cells pro-
duced more TNF-α, seemed to be somewhat more cytotoxic 
but did not express more CD57 than unlicensed cells. We also 
measured differences in IFN-γ production, the cytokine that is 
commonly tested in functional studies of NK cells. We found 
no differences, but again, we consider these results with caution 
because in our hands only few NK cells ex vivo produce IFN-γ 
when stimulated with target cells without being cultured in 
the presence of IL2/IL-12/IL-18 (20). Licensed and unlicensed 
CD56dim NK cells produced similar quantities of IFN-γ after 
stimulation with cytokines (data not shown), but this result is not 
more than had to be expected because the culture with cytokines 
would simply annul potential differences between licensed and 
unlicensed NK cells.
cOnclUsiOn
In conclusion, we found no impact of licensing on the expression 
of T-bet and Eomes.
Because T-bet and Eomes are the master regulators of NK 
cell maturation, these results are hard to reconcile with the 
model in which licensing induces maturation directly. However, 
because we also found that the effect of licensing was not easily 
substantiated for classical maturation-associated attributes, such 
as cytokine production, cytotoxicity, and expression of CD57, 
we believe that this finding should be interpreted with caution. 
In fact, human NK cells may not be ideal to study the effect of 
licensing on maturation because the circumstances in vivo that 
may bypass the need for licensing are hard to define.
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